Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Seth Boydstun

Orthopaedic Surgery Oklahoma City, OK Medical Doctor

NPI 1598179111 CMS profile 1091877

9600 Broadway Ext, Oklahoma City, OK 73114

Open in the dashboard

General payments

$26,115

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Seth Boydstun of Oklahoma City, OK is reported in the CMS Open Payments database as having received $26,115 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $174 2
2024 General $75 3
2023 General $1,052 14
2022 General $203 7
2021 General $1,389 10
2020 General $471 5
2019 General $22,751 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seth Boydstun
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Seth Boydstun were reported at $174. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Seth Boydstun Orthopaedic Surgery median Middle half National median
2019 $22,751 $644 $140–$2,844 $163
2020 $471 $312 $75–$1,860 $114
2021 $1,389 $520 $117–$2,495 $132
2022 $203 $598 $128–$2,731 $149
2023 $1,052 $461 $128–$2,264 $160
2024 $75 $497 $134–$2,475 $164
2025 $174 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $21,361 14 payments
  2. Pylant Medical $2,345 8 payments
  3. Micromed Inc $1,137 1 payment
  4. Stryker Corporation $419 9 payments
  5. Medical Device Business Services, Inc. $319 1 payment
  6. Zimmer Biomet Holdings, Inc. $149 1 payment
  7. Smith+Nephew, Inc. $56 3 payments
  8. Innovation Technologies Inc $50 2 payments
  9. Bioventus LLC $44 2 payments
  10. Avanos Medical $37 2 payments
  11. Other $198 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $20,000 1 payment
  2. Education $3,691 4 payments
  3. Food and Beverage $1,950 46 payments
  4. Travel and Lodging $474 2 payments
Products named General payments · program years 2019–2025
  1. ACCOLADE $181 5 payments
  2. Persona $149 1 payment
  3. CINCHLOCK $74 1 payment
  4. INSPACE $66 1 payment
  5. OMEGA $66 1 payment
  6. ALPHAVENT $59 1 payment
  7. Irrisept $50 2 payments
  8. MAKO $38 1 payment
  9. ON-Q* PUMP AND ACCESSORIES $37 2 payments
  10. Restrata Wound Matrix $34 1 payment
  11. Other $331 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

698

Median for Orthopedic Surgery: 203

Drug cost

$4,917

Median for Orthopedic Surgery: $1,433

Branded share of claims

47.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 210 $2,194
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 95 $1,062
Meloxicam Generic 205 $846
Tramadol Hcl Generic 42 $180
Ondansetron Odt Ondansetron Brand 13 $149
Ibuprofen Generic 11 $134
Clindamycin Hcl Generic 19 $122
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $83
Gabapentin Generic 16 $73
Amoxicillin Generic 73 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$193,448

Medicare's payments for the services billed

Medicare patients

390

Average age 74

Services billed

1,490

229 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 41%
Diabetes 27%
Atrial fibrillation 22%
Depression 20%
Chronic kidney disease 18%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record